Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 42

1.

Anaplastic Lymphoma Kinase: role in specific tumours, and development of small molecule inhibitors for cancer therapy.

Ardini E, Magnaghi P, Orsini P, Galvani A, Menichincheri M.

Cancer Lett. 2010 Dec 28;299(2):81-94. doi: 10.1016/j.canlet.2010.09.001. Epub 2010 Oct 8. Review.

PMID:
20934803
2.

The emerging pathogenic and therapeutic importance of the anaplastic lymphoma kinase gene.

Kelleher FC, McDermott R.

Eur J Cancer. 2010 Sep;46(13):2357-68. doi: 10.1016/j.ejca.2010.04.006. Epub 2010 May 5. Review.

PMID:
20451371
3.

Targeting oncogenic ALK: a promising strategy for cancer treatment.

Grande E, Bolós MV, Arriola E.

Mol Cancer Ther. 2011 Apr;10(4):569-79. doi: 10.1158/1535-7163.MCT-10-0615. Review. Erratum in: Mol Cancer Ther. 2011 Aug;10(8):1529.

4.

Anaplastic lymphoma kinase inhibitors as anticancer therapeutics: a patent review.

Mesaros EF, Ott GR, Dorsey BD.

Expert Opin Ther Pat. 2014 Apr;24(4):417-42. doi: 10.1517/13543776.2014.877890. Epub 2014 Jan 30. Review.

PMID:
24476492
5.

Development of anaplastic lymphoma kinase (ALK) small-molecule inhibitors for cancer therapy.

Li R, Morris SW.

Med Res Rev. 2008 May;28(3):372-412. Review.

PMID:
17694547
6.

Anaplastic lymphoma kinase rearrangement in lung cancer: its biological and clinical significance.

Toyokawa G, Seto T.

Respir Investig. 2014 Nov;52(6):330-8. doi: 10.1016/j.resinv.2014.06.005. Epub 2014 Jul 30. Review.

PMID:
25453376
7.
8.

Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy.

Webb TR, Slavish J, George RE, Look AT, Xue L, Jiang Q, Cui X, Rentrop WB, Morris SW.

Expert Rev Anticancer Ther. 2009 Mar;9(3):331-56. doi: 10.1586/14737140.9.3.331. Review.

9.

Insights into brain metastasis in patients with ALK+ lung cancer: is the brain truly a sanctuary?

Toyokawa G, Seto T, Takenoyama M, Ichinose Y.

Cancer Metastasis Rev. 2015 Dec;34(4):797-805. doi: 10.1007/s10555-015-9592-y. Review.

10.

Role of anaplastic lymphoma kinase inhibition in the treatment of non-small-cell lung cancer.

Croegaert K, Kolesar JM.

Am J Health Syst Pharm. 2015 Sep 1;72(17):1456-62. doi: 10.2146/ajhp140836. Review.

PMID:
26294238
11.

Treatment of ALK-Rearranged Non-Small Cell Lung Cancer: Recent Progress and Future Directions.

Cameron L, Solomon B.

Drugs. 2015 Jul;75(10):1059-70. doi: 10.1007/s40265-015-0415-9. Review.

PMID:
26076736
12.

ALKoma: a cancer subtype with a shared target.

Mano H.

Cancer Discov. 2012 Jun;2(6):495-502. doi: 10.1158/2159-8290.CD-12-0009. Epub 2012 May 21. Review.

13.

Oncogenic mutations of ALK in neuroblastoma.

Ogawa S, Takita J, Sanada M, Hayashi Y.

Cancer Sci. 2011 Feb;102(2):302-8. doi: 10.1111/j.1349-7006.2010.01825.x. Review.

14.

Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases.

Rodig SJ, Shapiro GI.

Curr Opin Investig Drugs. 2010 Dec;11(12):1477-90. Review.

PMID:
21154129
15.

ALK inhibitors in the treatment of advanced NSCLC.

Gridelli C, Peters S, Sgambato A, Casaluce F, Adjei AA, Ciardiello F.

Cancer Treat Rev. 2014 Mar;40(2):300-6. doi: 10.1016/j.ctrv.2013.07.002. Epub 2013 Aug 7. Review.

PMID:
23931927
16.

Inhibitors of the anaplastic lymphoma kinase.

Mologni L.

Expert Opin Investig Drugs. 2012 Jul;21(7):985-94. doi: 10.1517/13543784.2012.690031. Epub 2012 May 22. Review.

PMID:
22612599
17.

Ceritinib (LDK378): a potent alternative to crizotinib for ALK-rearranged non-small-cell lung cancer.

Li S, Qi X, Huang Y, Liu D, Zhou F, Zhou C.

Clin Lung Cancer. 2015 Mar;16(2):86-91. doi: 10.1016/j.cllc.2014.09.011. Epub 2014 Oct 13. Review.

PMID:
25458559
18.

Treatment and detection of ALK-rearranged NSCLC.

Peters S, Taron M, Bubendorf L, Blackhall F, Stahel R.

Lung Cancer. 2013 Aug;81(2):145-54. doi: 10.1016/j.lungcan.2013.03.017. Epub 2013 Jun 12. Review.

PMID:
23769207
19.

ALK inhibitors: what is the best way to treat patients with ALK+ non-small-cell lung cancer?

Toyokawa G, Seto T.

Clin Lung Cancer. 2014 Sep;15(5):313-9. doi: 10.1016/j.cllc.2014.05.001. Epub 2014 Jun 2. Review.

PMID:
24984564
20.

Targeting anaplastic lymphoma kinase in lung cancer.

Shaw AT, Solomon B.

Clin Cancer Res. 2011 Apr 15;17(8):2081-6. doi: 10.1158/1078-0432.CCR-10-1591. Epub 2011 Feb 2. Review.

Supplemental Content

Support Center